The U.S. Food and Drug Administration will meet its targets for completing reviews of new drugs despite mass firings at the ...

The Food and Drug Administration is phasing out the use of petroleum-based synthetic dyes by the end of 2026 - a change that ...

As pressure grows to get artificial colors out of the U.S. food supply, the shift may well start at Abby Tampow’s laboratory ...

Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

President Trump’s first 100 days have roiled health and science as part of the administration’s plan to reshape the federal ...

Multiple current and laid-off FDA employees said the abrupt layoffs had resulted in delays and disruptions to the agency's ...

The notion that we can simultaneously demand expedited approvals while gutting the agency is misguided.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

The U.S. Food and Drug Administration has delayed its decision on marketing approval for Stealth BioTherapeutics' treatment for a rare genetic condition that typically affects boys, the drug developer ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...

Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat ...